Thursday, October 9, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Financial Performance of Jasper Therapeutics for the Year Ending December 31 2023

Elaine Mendonca by Elaine Mendonca
March 4, 2024
in Breaking News
0
Biotechnology Markets and money
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Jasper Therapeutics recorded a net loss of $16.6 million and $64.5 million for the three months and the year ended on December 31, 2023, respectively. The basic and diluted net loss per share for common stockholders were $1.50 and $6.18 during the same periods. The company’s cash and cash equivalents totaled $86.9 million as of December 31, 2023. Research and development expenses for the year ended December 31, 2023, amounted to $51.8 million, with stock-based compensation expenses of $1.6 million included. General and administrative expenses for the same period were $17.1 million, with stock-based compensation expenses of $3.6 million.

—

On March 4, 2024, Jasper Therapeutics reported a net loss of $16.6 million and $64.5 million for the three months and the year ending on December 31, 2023. The basic and diluted net loss per share attributable to common stockholders were $1.50 and $6.18 for the same periods. Moreover, the company’s cash and cash equivalents as of December 31, 2023, were reported at $86.9 million. Research and development expenses for the year ending December 31, 2023, were $51.8 million, which included stock-based compensation expenses of $1.6 million. General and administrative expenses for the same period were $17.1 million, with stock-based compensation expenses of $3.6 million.

[bs_slider_forecast ticker=”JSPR”]

JSPR Stock Shows Strong Performance with Positive Price Momentum in Pre-Market Trading

On March 4, 2024, JSPR stock had a strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. This indicates positive price momentum for the stock. The price of JSPR shares had increased by $0.83 since the market last closed, representing a 3.91% rise. In pre-market trading on March 4, the stock had risen by an additional $0.67. This strong performance suggests that investors have confidence in JSPR and are optimistic about its future prospects. It is important for investors to continue monitoring JSPR stock and staying informed about any news or developments that may impact its performance.

Currently Playing

JSPR Stock Performance Review: Mixed Data Leaves Investors Uncertain on March 4, 2024

On March 4, 2024, investors in JSPR stock may have been feeling uncertain about the company’s financial performance based on the available data. According to CNN Money, JSPR’s total revenue information was currently unavailable, leaving investors without a key indicator of the company’s financial health.

The data that was available showed that JSPR had experienced a decrease in net income over the past year. The company reported a net income of -$37.69 million for the past year, which was a 23.0% decrease from the previous year. In the most recent quarter, JSPR reported a net income of -$17.54 million, representing a 9.1% decrease from the previous quarter.

Despite the decrease in net income, there was a glimmer of hope for investors in the form of earnings per share (EPS) data. JSPR reported an EPS of -$10.33 for the past year, which actually represented a 61.59% increase from the previous year. However, in the most recent quarter, the company reported an EPS of -$1.60, which was an 8.61% decrease from the previous quarter.

Overall, the mixed performance data for JSPR on March 4, 2024, may have left investors feeling uncertain about the company’s future prospects. While the increase in EPS over the past year was a positive sign, the decreases in net income over the same period could be cause for concern. Without more information on the company’s total revenue, investors may have been left wondering about JSPR’s overall financial health and future performance.

[stock_market_chart symbol=”JSPR” range=”3mo” interval=”1d” settings='{“primaryChartType”:”smoothedLine”,”secondaryChartType”:”column”,”width”:”100%”,”height”:”500px”,”marginTop”:0,”marginBottom”:0,”marginLeft”:10,”marginRight”:10,”primaryPanelTitle”:”Price”,”secondaryPanelTitle”:”Volume”,”fontSize”:14,”color”:”#383838″,”primaryLineColor”:”#5679ff”,”primaryLineColorAlpha”:0.15,”secondaryLineColor”:”#5679ff”,”secondaryLineColorAlpha”:0.15,”backgroundColor”:”#fff”,”gridColor”:”#e0e0e0″,”gridAlpha”:0.8,”cursorColor”:”#020202″,”cursorAlpha”:0.8,”scrollbarBackgroundColor”:”#e8e8e8″,”scrollbarSelectedBackgroundColor”:”#f7f7f7″,”scrollbarGraphFillColor”:”#435dc2″,”scrollbarSelectedGraphFillColor”:”#92a8fc”,”primaryLineThickness”:2,”secondaryLineThickness”:1,”gridThickness”:1,”precision”:2,”thousandsSeparator”:”,”,”decimalSeparator”:”.”,”usePrefixes”:false,”searchMode”:”search”,”mouseWheelZoomEnabled”:false,”cursorEnabled”:true,”exportEnabled”:true,”scrollbarEnabled”:true,”legendEnabled”:true,”periods”:”1D,1M,YTD,ALL”,”defaultPeriod”:”1M”}’]

Tags: JSPR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_ projections

Financial Analysts Bullish on Li Auto Stock

Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands

Lyfts Stock Rises After Upgrade from RBC Capital

Pharmaceutical Markets and money

Analyst Raghuram Selvaraju Reiterates Buy Rating for BridgeBio Pharma with 47 Price Target

Recommended

Lennox Stock

Is Lennox International Stock Caught in an Unrelenting Downturn?

1 month ago
Plug Power Stock

Plug Power Faces Investor Dilemma Amid Share Dilution Concerns

2 weeks ago
Uber Stock

Uber Stock: Strong Earnings Met With Market Skepticism

2 months ago
Block Stock

A Tale of Two Titans: Block and PayPal’s Divergent Fintech Paths

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BigBear.ai BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Credit Scoring War Erupts as Fair Isaac Faces Aggressive Price Challenge

Micron’s AI-Driven Surge Powers Record Financial Performance

Nio’s Growth Paradox: Record Deliveries Clash With Profitability Concerns

Deckers Outdoor Stock: Is the Growth Story Unraveling?

L3Harris Shares Reach Unprecedented Heights on Major Contract Wins

Amazon’s Billion-Euro Bet on European Expansion

Trending

Tilray Stock
Cannabis

Tilray Faces Critical Earnings Test Amid Market Rally

by Dieter Jaworski
October 9, 2025
0

Today represents a pivotal moment for Tilray's stock as the cannabis company prepares to release quarterly results...

CleanSpark Stock

CleanSpark Shares Surge as Bitcoin Mining Operations Accelerate

October 9, 2025
Virgin Galactic Stock

Virgin Galactic Stock: CFO’s Major Purchase Signals Confidence

October 9, 2025
Fair Isaac Stock

Credit Scoring War Erupts as Fair Isaac Faces Aggressive Price Challenge

October 9, 2025
Micron Stock

Micron’s AI-Driven Surge Powers Record Financial Performance

October 9, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Tilray Faces Critical Earnings Test Amid Market Rally
  • CleanSpark Shares Surge as Bitcoin Mining Operations Accelerate
  • Virgin Galactic Stock: CFO’s Major Purchase Signals Confidence

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com